OVERVIEW

GHRP‑2 (5 mg × 10) and CJC‑1295 no DAC (5 mg × 10) is a research peptide combination designed to stimulate endogenous growth hormone (GH) release through complementary mechanisms. GHRP‑2 is a synthetic growth hormone-releasing peptide that binds to the ghrelin receptor (GHS‑R1a), promoting pulsatile GH secretion and increasing levels of insulin-like growth factor-1 (IGF-1). CJC‑1295 no DAC is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the anterior pituitary to release GH in a physiologically pulsatile manner without extending its half-life, unlike versions with a drug affinity complex (DAC). When used together in research, these peptides engage distinct receptor pathways — GHRP‑2 through the ghrelin receptor and CJC‑1295 through the GHRH receptor — potentially enhancing GH pulse amplitude and duration. Researchers use this combination to study GH regulation, metabolism, tissue repair, and other physiological processes related to the somatotropic axis in controlled laboratory and preclinical models.

Despite preclinical interest, this peptide blend is not approved by the U.S. Food and Drug Administration for therapeutic or medical use in humans. Evidence for its safety, efficacy, and optimal dosing primarily comes from laboratory studies, animal research, or small human trials. Products marketed with GHRP‑2 and CJC‑1295 no DAC are usually labeled for research use only, meaning purity and quality may vary between sources. Self-administration outside research or clinical settings carries potential health, ethical, and legal risks. Individuals exploring growth hormone modulation should rely on evidence-based treatments and consult qualified healthcare professionals rather than unregulated peptide compounds.